Director Hemrajani Rekha buys 30,000 ALXO shares at $1.55; holdings surge 1000.0% to 33,000 shares amid -91.1% 52-week drawdown
Director Hemrajani Rekha purchased 30,000 shares of ALX Oncology at $1.55 on 2024-12-02, increasing her holdings from 3,000 to 33,000 shares—a net increase of 1000.0% on her prior position. The stock trades at $1.56 currently, down -91.1% from its 52-week high of $17.56, and the company remains unprofitable with net income of $-30.7M against quarterly revenue of $527.0K. This represents a substantial proportional increase in director ownership at a depressed absolute price level, though the timing occurs within a modest recent 30-day recovery of +4.7% after a steeper 90-day decline of -21.6%. The transaction signals meaningful insider capital deployment in a distressed biotech; investors should monitor whether this reflects board-level conviction in recovery prospects or simply opportunistic accumulation at historic lows given the company's negative earnings trajectory.